Draft:National Resilience

From Wikipedia, the free encyclopedia
National Resilience, Inc.
Industry
  • Biotechnology
  • Pharmaceutical
FoundedNovember 2020; 3 years ago (2020-11)
FounderRobert Nelson
HeadquartersSan Diego, California, United States
Number of locations
9
Area served
Worldwide
Key people
Products
Subsidiaries
Websiteresilience.com

National Resilience, operating primarily as Resilience, is a biomanufacturing and biotechnology company that develops gene therapy, vaccines, viral vectors and other therapeutic protein products. It is headquartered in San Diego, California and has nine additional manufacturing facilities open or in development, including in Missisauga, Boston, the San Francisco Bay Area, North Carolina, Philadelphia, and northern Florida.[1]

Resilience was founded to address problems identified in the private sector during the COVID-19 pandemic in the United States, with the intention to strengthen medical supply chains.[2][3] The company works with the Government of Canada and United States Department of Defense, as well as a range of biotechnology companies and universities.

Resilience is a member of the Alliance for Regenerative Medicine[4] and Biotechnology Innovation Organization (BIO).[5]

History[edit]

Conception and founding[edit]

The idea for Resilience is described as having originated from discussions between ARCH Venture Partners co-founder Robert Nelson and Luciana Borio, then-Vice President of In-Q-Tel, the venture capital firm of the Central Intelligence Agency.[6][7]

Resilience launched in November 2020 under the leadership of Rahul Singhvi (of Flagship Pioneering, Novavax and Takeda Vaccines) and Nelsen.[8] It received significant seed funding from ARCH and 8VC, beginning operations with a total of $800 million in capital.[2] Former Food and Drug Administration commissioner Scott Gottlieb was brought on to Resilience's board of directors, as was Patrick Wang, former executive vice president at Genentech.

Rapid expansion[edit]

In March 2021, Resilience acquired a 310,000 square foot manufacturing facility from Sanofi, formerly used for its Genzyme business.[8] The facility is located on land owned by Harvard University in Boston, Massachessets.[9] Additionally, the company purchased a second location in Mississauga, Ontario, Canada, measuring 136,000 square feet, and took over a Bluebird bio site in North Carolina.[10] In April 2021, Resilience acquired Ology Bioservices.[11] Ology had been awarded a contract in February 2020 from the United States Government to develop an advanced monoclonal antibody therapy against COVID-19.[12]

In May 2021, the Government of Canada announced a CAD $200 million investment in Resilience's Mississauga operation, Resilience Biotechnologies.[13] The City of Mississauga issued a statement in support of the investment, emphasizing that the federal funding would allow the company to manufacture 112 to 640 million doses of mRNA vaccines annually and strengthen the country's ability to respond to future pandemics.[14]

In September 2021, Moderna announced that Resilience would manufacture the synthetic mRNA components of its mRNA-1273 COVID-19 vaccine for delivery worldwide, including its newer "bivalent" product.[15][16]

In June 2022, Resilience announced it had raised an additional $625 million in funding from undisclosed investors.[8] In March 2023, the company received $410 million in debt financing from the United States Department of Defense and the U.S. International Development Finance Corporation.[3][17][18]

On February 5, 2024, Resilience announced a partnership with Taiwan Bio-Manufacturing Corporation (TBMC) to construct a research and manufacturing facility. Resilience received an undisclosed ownership stake in TBMC as part of the deal.[3]

Organization[edit]

Reliance's leadership is primarily made up of current and former pharmaceutical executives, politicians, regulatory officials, and venture capitalists.[19] It additionally employs advisors including Mark McClellan, former commissioner of the Food and Drug Administration.

Executive Team[edit]

  • Rahul Singhvi - Co-founder and Chief Executive Officer
  • Sandy Mahatme - President, Chief Operating and Financial Officer
  • Viet Nguyen - Chief Manufacturing Officer
  • Syed T. Husain - Chief Commercial Officer
  • Rich Stoner - Chief Scientific Officer
  • Elliot Menschik - Chief Digital Officer
  • Ori Solomon - Chief Legal Officer
  • Mara Strandlund - Chief People Officer
  • Alex Szidon - Chief Business Officer

Board of Directors[edit]

Investors[edit]

Investors in Resilience include 8VC, Arch Venture Partners, GV (the venture capital arm of Alphabet Inc.) and New Enterprise Associates.[19]

Clients[edit]

Resilience's clientele includes pharmaceutical and biotechnology companies, United States government agencies, and academic institutions.

The company works with Takeda Pharmaceutical Company's plasma-derived therapies unit, and manufactures Opus Genetics' gene therapies for inherited renal diseases.[1] Bluebird bio partnered with the company in order to accelerate its cell therapy portfolio.[10]

Its work with the United States Department of Defense includes manufacturing their monoclonal antibody therapy against botulinum neurotoxins.

Its academic collaborators include the Children's Hospital of Philadelphia, Harvard University, and the MD Anderson Cancer Center.

References[edit]

  1. ^ a b Freeman, Mike (2022-06-08). "La Jolla-based National Resilience lands $625 million for next-generation biomanufacturing". San Diego Union-Tribune. Archived from the original on 2022-10-08. Retrieved 2022-10-29.
  2. ^ a b Shieber, Jonathan (2020-11-23). "Resilience raises over $800 million to transform pharmaceutical manufacturing in response to COVID-19". TechCrunch. Archived from the original on 2022-10-02. Retrieved 2022-10-29.
  3. ^ a b c Graves, Brad (2024-02-22). "National Resilience Expanding International Footprint Again". San Diego Business Journal. Archived from the original on 2024-03-27. Retrieved 2024-03-27.
  4. ^ "Members & Profiles". Alliance for Regenerative Medicine. Archived from the original on 2024-02-26. Retrieved 2024-03-27.
  5. ^ "BIO Member Directory". Biotechnology Innovation Organization. Archived from the original on 2022-09-30. Retrieved 2022-10-30.
  6. ^ Brennan, Zachary (2021-07-26). "UPDATED: Bob Nelsen's ARCH adds FDA, biodefense expertise with appointment of Luciana Borio". Endpoints News. Archived from the original on 2022-08-24. Retrieved 2022-10-29.
  7. ^ Mast, Jason (2020-11-23). "Bob Nelsen raises $800M and recruits a star-studded board to build the 'Foxconn' of biotech". Endpoints News. Archived from the original on 2022-08-28. Retrieved 2022-10-29.
  8. ^ a b c Kansteiner, Fraiser (2021-03-24). "National Resilience, months after launching with $800M, snags Sanofi biomanufacturing plant". Fierce Pharma. Retrieved 2022-10-29.
  9. ^ Powell, Alvin (2021-03-22). "National Resilience takes over Genzyme/Sanofi building in Allston". Harvard Gazette. Archived from the original on 2022-10-25. Retrieved 2022-10-29.
  10. ^ a b Sagonowsky, Eric (2021-07-28). "National Resilience forks over $110M for North Carolina manufacturing site in bluebird bio cell therapy partnership". Fierce Pharma. Archived from the original on 2022-10-29. Retrieved 2022-10-29.
  11. ^ Sterling, John (2021-04-13). "Resilience Acquires Ology Bioservices". GEN - Genetic Engineering and Biotechnology News. Archived from the original on 2022-04-12. Retrieved 2022-10-29.
  12. ^ "MABS Manufacturing Platform Development Agreement with Ology - W911QY-20-9-0003" (PDF). United States Department of Health and Human Services. 2020-02-21. Archived (PDF) from the original on 2021-12-11. Retrieved 2022-10-29.
  13. ^ Innovation, Science and Economic Development Canada (2021-05-18). "Government of Canada continues to strengthen Canada's biomanufacturing sector". Government of Canada. Archived from the original on 2022-10-29. Retrieved 2022-10-29.
  14. ^ "City of Mississauga Thrilled with $200 Million Investment to Expand Resilience Biotechnologies Inc.'s Vaccine Manufacturing in Mississauga". City of Mississauga. 2021-05-19. Archived from the original on 2022-10-29. Retrieved 2022-10-29.
  15. ^ Higgins-Dunn, Noah (2021-09-08). "Moderna taps National Resilience's new Canadian manufacturing site for COVID-19 vaccine production duties". Fierce Pharma. Archived from the original on 2022-10-29. Retrieved 2022-10-29.
  16. ^ Herper, Matthew (2021-09-08). "Moderna turns to biotech startup to ramp up Covid vaccine manufacturing". STAT News. Archived from the original on 2024-03-30. Retrieved 2024-03-30.
  17. ^ Kansteiner, Fraiser (2023-03-28). "As US plots biomanufacturing boost, National Resilience nets $410M loan from Defense Department". Fierce Pharma. Archived from the original on 2023-06-06. Retrieved 2024-03-27.
  18. ^ "Brown Meets with National Resilience CEO to Discuss $410 Million Loan that will Bolster Domestic Pharmaceutical Supply Chain in Ohio". U.S. Senator Sherrod Brown of Ohio. 2023-10-17. Retrieved 2024-03-27.
  19. ^ a b "Meet Our Team". Resilience. 2021-12-07. Archived from the original on 2022-10-30. Retrieved 2022-10-30.

External links[edit]

Category:Biotechnology companies Category:Gene therapy Category:COVID-19 vaccine producers

Retrieved from "https://en.wikipedia.org/w/index.php?title=Draft:National_Resilience&oldid=1220889919"